Bio­phar­ma's Chi­na plan gets a boost from patent pro­tec­tions sealed in now of­fi­cial trade deal

As in­ter­na­tion­al re­la­tions ex­perts con­tin­ue to cast skep­ti­cism on the “phase one” US-Chi­na trade deal signed Wednes­day, multi­na­tion­al drug­mak­ers found much to be cheer­ful about.

Specif­i­cal­ly, the doc­u­ment in­cludes three pro­vi­sions re­lat­ed to phar­ma­ceu­ti­cal patent dis­pute res­o­lu­tion, patent term ex­ten­sion and coun­ter­feit med­i­cines, promis­ing to strength­en pro­tec­tion for drugs at a time Chi­na’s reg­u­la­to­ry agency has sped up re­views and short­ened the time gap be­tween over­seas and Chi­nese OKs.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.